• Jump to content
  • Jump to navigation
  • Jump to search
Bionor Pharma
Search
  • Home
  • Vaccines
  • Nutraceuticals
  • Investors
  • About Bionor Pharma
  • You are here:
    1. Frontpage
    2. Sitemap

Sitemap

  • Home
  • Vaccines
    • History
    • Platform technology
    • HIV: Vacc-4x Therapeutic vaccine
    • HIV: Vacc-4x Development
    • HIV: Vacc-C5
    • Hepatitis C (HCV)
    • Cervical cancer (HPV)
    • Influenza
    • Publications
    • Advisory Boards
  • Nutraceuticals
    • History
    • NutriPro products
    • Nutri5 products
    • Research & documentation
  • Investors
    • Share information
    • Business model
    • Financial reports
    • Governance
    • 20 largest shareholders
    • Financial analysts
    • Downloads
  • About Bionor Pharma
    • Board of Directors
    • Management
    • Career opportunities
    • Contact us
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Sitemap

Latest News Full archive ››

  • 17.02.2012FOURTH QUARTER AND FULL-YEAR RESULTS 2011
  • 16.02.2012Related articles in 2012 regarding Vacc-4x
  • 15.02.2012Results for viral load on Vacc-4x

CalendarFull calendar ››

  • Financial calendar 2012 for Bionor Pharma

E-mail alert More info ››

      • Vaccines
      • About Bionor Pharma
      • Sitemap
    • Bionor Pharma ASA Kronprinsesse Märthas Plass 1 P.O. Box 1477 Vika, NO-0116 Oslo, Norway, Tel.: +47 23 01 09 60, Fax +47 23 01 09 70 

      Site by Pinpoint & Idium